- Home
- FCAP vs RNAC Comparison
FCAP vs RNAC Comparison
Compare FCAP & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | RNAC |
|---|---|---|
| Founded | 1891 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.7M | 238.9M |
| IPO Year | 1998 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FCAP | RNAC |
|---|---|---|
| Price | $60.63 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 14.3K | ★ 108.1K |
| Earning Date | 04-24-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 36.97 | N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $7,170,000.00 | $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.17 | ★ N/A |
| Revenue Growth | ★ 1.57 | N/A |
| 52 Week Low | $37.64 | $5.60 |
| 52 Week High | $71.00 | $11.00 |
Technical Indicators
Market Signals| Indicator | FCAP | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 29.37 |
| Support Level | $59.91 | $5.88 |
| Resistance Level | $64.48 | $7.63 |
| Average True Range (ATR) | 1.77 | 0.43 |
| MACD | -0.20 | -0.11 |
| Stochastic Oscillator | 29.14 | 11.91 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.